Rakuten Medical, Inc.
11080 Roselle St
50 articles about Rakuten Medical, Inc.
Rakuten Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10th, 2024
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell-targeting photoimmunotherapy treatments based on its proprietary Alluminox™ platform, today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference being held January 8-11, 2024.
Rakuten Medical Presents AI-based Study in Two Posters on Immune Characteristics in Responders and Cellular Level Drug Quantification of Alluminox Treatment (Photoimmunotherapy) at SITC 2023
Rakuten Medical, Inc. today announced the presentation of two posters of AI-based analyses at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held November 3-5, 2023, in San Diego, CA (SITC 2023).
Rakuten Medical, Inc. announced that the Company will present at the 14th Annual Jefferies London Healthcare Conference being held in London, UK, on November 14-16, 2023.
Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa
Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform announces an exclusive licensing and commercialization agreement with Hikma Pharmaceuticals PLC, a multinational pharmaceutical company for the Middle East and North Africa.
Rakuten Medical, Inc. today announced it will host a virtual R&D Day on the preliminary safety and efficacy findings from its open-label Phase 1b/2 study of Alluminox™ treatment using ASP-1929 in combination with anti-PD-1 therapy in recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC).
New Preliminary Findings on Potential Response Indicator of Rakuten Medical's Alluminox Treatment from Phase 2 Window of Opportunity Study at SNMMI 2023
Rakuten Medical, Inc. announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging 2023 Annual Meeting held from June 24 to 27.
Rakuten Medical to Start a Global Phase 3 Trial of Alluminox™ Treatment using ASP-1929 for Recurrent Head and Neck Cancer in India
Rakuten Medical, Inc. (Rakuten Medical) today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical trial (ASP-1929-301/ClinicalTrials.gov Identifier: NCT03769506) evaluating Alluminox treatment (photoimmunotherapy) using ASP-1929 in patients with locoregional.
Rakuten Medical to Present New Data of Alluminox™ Treatment using ASP-1929 in Combination with anti-PD-1 at AHNS 2023
Rakuten Medical, Inc. announced that the abstract 'Safety and efficacy findings from a phase 1b/2 open-label study of a novel combination of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma' has been selected for a podium presentation at this year's American Head and Neck Society 11th International Conference on Head and Neck Cancer.
Rakuten Medical Presented at the 41st Annual J.P. Morgan Healthcare Conference on the Progress of its Pipeline including its Newly Added Antibody-Dye Conjugate RM-0256, Commercial Growth in Japan, and Important Milestones for the Next Few Years
Mickey Mikitani, Co-CEO of Rakuten Medical, Inc. gave a presentation to investors from around the world at the 41st Annual J.P. Morgan Healthcare Conference (JPM2023) on January 10, 2023, in San Francisco, California, U.S.
Rakuten Medical to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10th, 2023
Rakuten Medical, Inc. will present on how the company has been advancing its technology, and how it plans to continue doing so, in order to reach more patients around the world at the 41st Annual J.P. Morgan Healthcare Conference being held January 9-12, 2023.
With the Establishment of India Entity, Mickey Mikitani, Co-CEO of Rakuten Medical Visits Respected Medical Institutions in India
Rakuten Medical, Inc. has newly established its subsidiary in India, Rakuten Medical Private Limited to strengthen its position in the country and expand its presence worldwide.
Rakuten Medical Taiwan Announces Commencing a Phase 2 Clinical Trial for Head and Neck Squamous Cell Carcinoma Photoimmunotherapy based on the Alluminox™ platform at 5 Leading Medical Centers and the Enrollment of First Patient
Rakuten Medical Taiwan, Inc. announced that their ASP-1929 Photoimmunotherapy Phase 2 clinical trial has enrolled and treated its first patient.
Rakuten Medical, Inc. has elected to discontinue use of the name "Illuminox," and to start using a new, evolved name "Alluminox™" for our proprietary, anti-cancer, photoimmunotherapy technology platform, which is comprised of drug, medical device, and other related technologies.
Rakuten Medical, Inc. (Rakuten Medical) and Shimadzu Corporation (Shimadzu) today announced enrollment of the first patient in the phase 2 clinical trial of ASP-1929 photoimmunotherapy with fluorescence imaging (Study number: ASP-1929-103) at the National Cancer Institute of the National Institutes of Health in the United States.
Rakuten Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10th, 2022
Rakuten Medical, Inc., a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.
Rakuten Medical Announces FDA Acceptance of an Investigational New Drug (IND) Application for RM-1995, a Conjugate of IR700 and anti-CD25 Antibody
Rakuten Medical, Inc announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug application to begin clinical studies of RM-1995 photoimmunotherapy in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.
Data from Phase 1/2a study of RM-1929 Photoimmunotherapy in Patients with Recurrent Head and Neck Squamous Cell Carcinoma was Published in Head and Neck
Rakuten Medical, Inc. announced that data from a phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma was accepted for publication in Head and Neck and published online on October 9th, 2021.
Rakuten Medical and Karkinos Healthcare Announce Strategic Partnership to Expand the Reach of Novel Cancer Care in India
Rakuten Medical Inc, and Karkinos Healthcare Private Limited announced a strategic collaboration to expand the reach of novel cancer care to India.
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
Financing will support Rakuten Medical's ongoing trials of ASP-1929 in several oncologic indications and research and development of additional pipeline therapies being developed using the Illuminox™ platform.